



The Commonwealth of Massachusetts
Office of Health and Human Services
Department of Public Health
Division of Health Professions Licensure
239 Causeway Street, Suite 500, 5th Floor, Boston, MA 02114
(617) 973-0800
(617) 973-0988 TTY

DEVAL L. PATRICK
GOVERNOR

JOHN W. POLANOWICZ
SECRETARY

CHERYL BARTLETT, RN
COMMISSIONER

May 21, 2014

Frequently Asked Questions: **Board Approved Zohydro™ ER Medication Guide**

Q: Do the Massachusetts Board of Registration in Pharmacy ("Board") emergency regulations pertaining to the dispensing of hydrocodone-only, extended release medications that are not in abuse-deterrent formulations require the pharmacist to provide any information when dispensing this product?

A: Yes, the Pharmacist **must** counsel **and** provide a written warning approved by the Board regarding the use and specific dangers of hydrocodone-only extended release medication that is not in an abuse deterrent formulation. The written warning must accompany each prescription of hydrocodone-only extended release medication dispensed by the pharmacist.

Q: Does the Zohydro Medication Guide meet this requirement?

A: Yes, on May 6, 2014, the Board approved the current FDA approved Medication Guide "Medication Guide ZOHYDRO™ ER (zoh-hye-droh) (hydrocodone bitartrate) Extended-Release Capsules, CII Reference ID: 3395199 / Issued October 2013 as the written warning to be provided with each prescription for hydrocodone-only, extended release medications that are not in abuse-deterrent formulations. The medication guide is available at: <http://www.fda.gov/downloads/Drugs/DrugSafety/UCM374009.pdf> last accessed 5/20/2014. At this time, the medication guide is the only approved written warning.